Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.

Decker MD, Greenberg DP, Johnson DR, Pool V.

Vaccine. 2019 Aug 14;37(35):5003-5008. doi: 10.1016/j.vaccine.2019.07.015. Epub 2019 Jul 10.

PMID:
31301919
2.

Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.

Young-Xu Y, Snider JT, van Aalst R, Mahmud SM, Thommes EW, Lee JKH, Greenberg DP, Chit A.

Vaccine. 2019 Mar 7;37(11):1484-1490. doi: 10.1016/j.vaccine.2019.01.063. Epub 2019 Feb 8.

3.

Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).

Robertson CA, Hedrick J, Bassily E, Greenberg DP.

Vaccine. 2019 Feb 14;37(8):1016-1020. doi: 10.1016/j.vaccine.2019.01.008. Epub 2019 Jan 19.

4.

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.

Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP.

Pediatr Infect Dis J. 2019 Mar;38(3):323-328. doi: 10.1097/INF.0000000000002227.

5.

Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients.

Talbot HK, Dunning AJ, Robertson CA, Landolfi VA, Greenberg DP, DiazGranados CA.

Open Forum Infect Dis. 2018 May 22;5(6):ofy115. doi: 10.1093/ofid/ofy115. eCollection 2018 Jun 1.

6.

Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.

Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A.

Expert Rev Vaccines. 2018 May;17(5):435-443. doi: 10.1080/14760584.2018.1471989. Epub 2018 May 16. Review.

PMID:
29715054
7.

Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.

Pool V, Tomovici A, Johnson DR, Greenberg DP, Decker MD.

Vaccine. 2018 Apr 19;36(17):2282-2287. doi: 10.1016/j.vaccine.2018.03.029. Epub 2018 Mar 21.

8.

Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.

Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, Greenberg DP, Bassily E, Klein NP.

Vaccine. 2018 Apr 12;36(16):2133-2138. doi: 10.1016/j.vaccine.2018.02.107. Epub 2018 Mar 14.

9.

Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.

Halperin SA, Donovan C, Marshall GS, Pool V, Decker MD, Johnson DR, Greenberg DP; Tdap Booster Investigators.

J Pediatric Infect Dis Soc. 2019 May 11;8(2):105-114. doi: 10.1093/jpids/pix113.

10.

Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.

Hansen J, Zhang L, Klein NP, Robertson CA, Decker MD, Greenberg DP, Bassily E, Baxter R.

Vaccine. 2017 Dec 14;35(49 Pt B):6879-6884. doi: 10.1016/j.vaccine.2017.09.032. Epub 2017 Sep 21.

11.

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.

Greenberg DP, Robertson CA, Talbot HK, Decker MD.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2058-2064. doi: 10.1080/21645515.2017.1344375.

12.

Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017.

Gershman MD, Angelo KM, Ritchey J, Greenberg DP, Muhammad RD, Brunette G, Cetron MS, Sotir MJ.

MMWR Morb Mortal Wkly Rep. 2017 May 5;66(17):457-459. doi: 10.15585/mmwr.mm6617e2. Erratum in: MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):490.

13.

Fluzone® High-Dose Influenza Vaccine.

Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP.

Expert Rev Vaccines. 2016 Dec;15(12):1495-1505. Epub 2016 Nov 14. Review.

PMID:
27813430
14.

Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.

Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.

Vaccine. 2016 Oct 17;34(44):5273-5278. doi: 10.1016/j.vaccine.2016.09.003. Epub 2016 Sep 15.

15.

Reply to Skowronski et al.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Clin Infect Dis. 2016 Nov 1;63(9):1267. Epub 2016 Aug 9. No abstract available.

PMID:
27506683
16.

Fluzone® Intradermal Quadrivalent Influenza Vaccine.

Robertson CA, Tsang P, Landolfi VA, Greenberg DP.

Expert Rev Vaccines. 2016 Oct;15(10):1245-53. doi: 10.1080/14760584.2016.1215246. Epub 2016 Aug 5. Review.

PMID:
27457797
17.

Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine.

Baxter R, Hansen J, Timbol J, Pool V, Greenberg DP, Johnson DR, Decker MD.

Hum Vaccin Immunother. 2016 Nov;12(11):2742-2748. Epub 2016 Jul 7.

18.

Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers.

Hansen J, Timbol J, Lewis N, Pool V, Decker MD, Greenberg DP, Klein NP.

Vaccine. 2016 Jul 29;34(35):4172-4179. doi: 10.1016/j.vaccine.2016.06.062. Epub 2016 Jun 30.

19.

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Clin Infect Dis. 2016 May 1;62(9):1092-1099. doi: 10.1093/cid/ciw085. Epub 2016 Feb 21.

20.

Highly differentiated human airway epithelial cells: a model to study host cell-parasite interactions in pertussis.

Guevara C, Zhang C, Gaddy JA, Iqbal J, Guerra J, Greenberg DP, Decker MD, Carbonetti N, Starner TD, McCray PB Jr, Mooi FR, Gómez-Duarte OG.

Infect Dis (Lond). 2016;48(3):177-88. doi: 10.3109/23744235.2015.1100323. Epub 2015 Oct 22.

21.

Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.

DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP.

Vaccine. 2015 Sep 11;33(38):4988-93. doi: 10.1016/j.vaccine.2015.07.006. Epub 2015 Jul 26.

22.

Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.

DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.

Vaccine. 2015 Aug 26;33(36):4565-71. doi: 10.1016/j.vaccine.2015.07.003. Epub 2015 Jul 14.

23.

Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical Centers.

Decker MD, DiazGranados CA, Chit A, Hosbach P, Robertson CA, Greenberg DP.

Clin Infect Dis. 2015 Oct 15;61(8):1344-5. doi: 10.1093/cid/civ547. Epub 2015 Jul 8. No abstract available.

PMID:
26157048
24.

Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.

Chit A, Roiz J, Briquet B, Greenberg DP.

Vaccine. 2015 Jan 29;33(5):734-41. doi: 10.1016/j.vaccine.2014.10.079. Epub 2014 Nov 11.

25.

Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age.

Marshall GS, Pool V, Greenberg DP, Johnson DR, Sheng X, Decker MD.

Clin Vaccine Immunol. 2014 Nov;21(11):1560-4. doi: 10.1128/CVI.00474-14. Epub 2014 Sep 17.

26.

Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine.

Decker MD, Hosbach P, Johnson DR, Pool V, Greenberg DP.

J Infect Dis. 2015 Feb 1;211(3):497-8. doi: 10.1093/infdis/jiu477. Epub 2014 Aug 25. No abstract available.

27.

Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK.

N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727.

28.

Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.

Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.

Pediatr Infect Dis J. 2014 Jun;33(6):630-6. doi: 10.1097/INF.0000000000000254.

PMID:
24445833
29.

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.

Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11.

30.

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.

Vaccine. 2013 Dec 5;31(50):6034-40. doi: 10.1016/j.vaccine.2013.09.012. Epub 2013 Sep 20.

PMID:
24055306
31.

Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not supported when data are stratified by age.

André P, Johnson DR, Greenberg DP, Decker MD.

Clin Infect Dis. 2013 Dec;57(11):1658-60. doi: 10.1093/cid/cit552. Epub 2013 Aug 15. No abstract available.

PMID:
23956165
32.

Prevention and control of influenza and dengue through vaccine development.

Greenberg DP, Robertson CA, Gordon DM.

Pediatr Ann. 2013 Aug;42(8):172-7. doi: 10.3928/00904481-20130723-12. Review.

PMID:
23910031
33.

Immune responses in infants whose mothers received Tdap vaccine during pregnancy.

Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, Greenberg DP, Kirkland KB, Talbot EA, Bernstein HH.

Pediatr Infect Dis J. 2013 Nov;32(11):1257-60. doi: 10.1097/INF.0b013e3182a09b6a.

PMID:
23799518
34.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
35.

Pneumococcal resistance and serotype 19A in Pittsburgh-area children with acute otitis media before and after introduction of 7-valent pneumococcal polysaccharide vaccine.

Hoberman A, Paradise JL, Shaikh N, Greenberg DP, Kearney DH, Colborn DK, Rockette HE, Kurs-Lasky M, McEllistrem MC, Zoffel LM, Balentine TL, Barbadora KA, Wald ER.

Clin Pediatr (Phila). 2011 Feb;50(2):114-20. doi: 10.1177/0009922810384259. Epub 2010 Nov 22.

PMID:
21098526
37.
38.

Current issues in adolescent immunization.

Brabin L, Greenberg DP, Hessel L, Hyer R, Ivanoff B, Van Damme P.

Vaccine. 2008 Aug 5;26(33):4120-34. doi: 10.1016/j.vaccine.2008.04.055. Epub 2008 May 12. Review.

PMID:
18617295
39.

Automated vascular geometric analysis of aortic aneurysms.

Goel VR, Greenberg RK, Greenberg DP.

IEEE Comput Graph Appl. 2008 May-Jun;28(3):76-86.

PMID:
18491709
40.

Mathematical analysis of DICOM CT datasets: can endograft sizing be automated for complex anatomy?

Goel VR, Greenberg RK, Greenberg DP.

J Vasc Surg. 2008 Jun;47(6):1306-12; discussion 1312. doi: 10.1016/j.jvs.2007.12.046. Epub 2008 Apr 18.

41.

Improving influenza vaccination rates of high-risk inner-city children over 2 intervention years.

Zimmerman RK, Hoberman A, Nowalk MP, Lin CJ, Greenberg DP, Weinberg ST, Ko FS, Fox DE.

Ann Fam Med. 2006 Nov-Dec;4(6):534-40.

42.

Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media.

Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, Forbes M, Greenberg DP, Dice B, Burrows A, Wackym PA, Stoodley P, Post JC, Ehrlich GD, Kerschner JE.

JAMA. 2006 Jul 12;296(2):202-11.

43.

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R; APERT Study Group.

Clin Infect Dis. 2006 Jul 15;43(2):151-7. Epub 2006 Jun 5.

PMID:
16779740
44.

Accurate direct illumination using iterative adaptive sampling.

Donikian M, Walter B, Bala K, Fernandez S, Greenberg DP.

IEEE Trans Vis Comput Graph. 2006 May-Jun;12(3):353-64.

PMID:
16640249
45.
46.

Characterization, distribution, and expression of novel genes among eight clinical isolates of Streptococcus pneumoniae.

Shen K, Gladitz J, Antalis P, Dice B, Janto B, Keefe R, Hayes J, Ahmed A, Dopico R, Ehrlich N, Jocz J, Kropp L, Yu S, Nistico L, Greenberg DP, Barbadora K, Preston RA, Post JC, Ehrlich GD, Hu FZ.

Infect Immun. 2006 Jan;74(1):321-30.

47.

Efficacy of an acellular pertussis vaccine among adolescents and adults.

Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, Edelman R, Edwards K; APERT Study Group.

N Engl J Med. 2005 Oct 13;353(15):1555-63.

48.

Parental perspectives on influenza immunization of children aged 6 to 23 months.

Nowalk MP, Zimmerman RK, Lin CJ, Ko FS, Raymund M, Hoberman A, Kearney DH, Greenberg DP.

Am J Prev Med. 2005 Oct;29(3):210-4.

PMID:
16168870
49.

Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents.

Greenberg DP.

Pediatr Infect Dis J. 2005 Aug;24(8):721-8. Review. Erratum in: Pediatr Infect Dis J. 2005 Nov;24(11):983.

PMID:
16094229
50.

Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.

Lin PL, Michaels MG, Green M, Mazariegos GV, Webber SA, Lawrence KS, Iurlano K, Greenberg DP.

Pediatrics. 2005 Jul;116(1):160-7.

PMID:
15995047

Supplemental Content

Loading ...
Support Center